npj Breast Cancer-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1001581, encodeId=bf861001581eb, content=有没有大神知道Waiting to Send Decision to Author是什么意思？是送审的意思吗？还以为是拒稿，等了9天了，还是这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jul 22 08:27:36 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194952, encodeId=1c4e219495215, content=Waiting to Send Decision to Author拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1c29228475, createdName=ms5000002109861368, createdTime=Sun Mar 24 00:19:34 CST 2024, time=2024-03-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=890079, encodeId=7e898900e9c0, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化研究 经验分享：今年首个IF6.0，刚中了一篇，整体要求还是很高，审稿人很专业，要求上传所有原始数据，测序数据要求上传NCBI等公共数据库。很有潜力的乳腺专刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be12166263, createdName=164205595_15230006, createdTime=Sun Oct 04 14:11:33 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183307, encodeId=893b218330e6d, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：未果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:07:04 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2183306, encodeId=0e6d218330648, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:06:27 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2131030, encodeId=8cae2131030ea, content=给共同作者发送了确认邮件是送审之前还是之后呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec888314364, createdName=ms5000000878333462, createdTime=Mon May 08 22:22:18 CST 2023, time=2023-05-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2124134, encodeId=87dc2124134d3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：“Manuscript Under Consideration” 都两个月了，应该是送审了吧，审稿速度真的好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82456516525, createdName=ms5000002097440921, createdTime=Thu Apr 06 16:03:46 CST 2023, time=2023-04-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1226584, encodeId=00891226584a5, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:08:09 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226583, encodeId=b29a12265835b, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:07:34 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193778, encodeId=b3881193e783d, content=<a href='/topic/show?id=b40310445682' target=_blank style='color:#2F92EE;'>#期刊推荐#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104456, encryptionId=b40310445682, topicName=期刊推荐)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=梅斯助教, createdTime=Tue Feb 15 21:44:47 CST 2022, time=2022-02-15, status=1, ipAttribution=)]

2021-07-22 ms4000001058776765

有没有大神知道Waiting to Send Decision to Author是什么意思？是送审的意思吗？还以为是拒稿，等了9天了，还是这样

94 27

展开27条回复

[GetPortalCommentsPageByObjectIdResponse(id=1001581, encodeId=bf861001581eb, content=有没有大神知道Waiting to Send Decision to Author是什么意思？是送审的意思吗？还以为是拒稿，等了9天了，还是这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jul 22 08:27:36 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194952, encodeId=1c4e219495215, content=Waiting to Send Decision to Author拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1c29228475, createdName=ms5000002109861368, createdTime=Sun Mar 24 00:19:34 CST 2024, time=2024-03-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=890079, encodeId=7e898900e9c0, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化研究 经验分享：今年首个IF6.0，刚中了一篇，整体要求还是很高，审稿人很专业，要求上传所有原始数据，测序数据要求上传NCBI等公共数据库。很有潜力的乳腺专刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be12166263, createdName=164205595_15230006, createdTime=Sun Oct 04 14:11:33 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183307, encodeId=893b218330e6d, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：未果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:07:04 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2183306, encodeId=0e6d218330648, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:06:27 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2131030, encodeId=8cae2131030ea, content=给共同作者发送了确认邮件是送审之前还是之后呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec888314364, createdName=ms5000000878333462, createdTime=Mon May 08 22:22:18 CST 2023, time=2023-05-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2124134, encodeId=87dc2124134d3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：“Manuscript Under Consideration” 都两个月了，应该是送审了吧，审稿速度真的好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82456516525, createdName=ms5000002097440921, createdTime=Thu Apr 06 16:03:46 CST 2023, time=2023-04-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1226584, encodeId=00891226584a5, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:08:09 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226583, encodeId=b29a12265835b, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:07:34 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193778, encodeId=b3881193e783d, content=<a href='/topic/show?id=b40310445682' target=_blank style='color:#2F92EE;'>#期刊推荐#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104456, encryptionId=b40310445682, topicName=期刊推荐)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=梅斯助教, createdTime=Tue Feb 15 21:44:47 CST 2022, time=2022-02-15, status=1, ipAttribution=)]

2024-03-24 ms5000002109861368 来自广东省

Waiting to Send Decision to Author拒稿吗

9 0

[GetPortalCommentsPageByObjectIdResponse(id=1001581, encodeId=bf861001581eb, content=有没有大神知道Waiting to Send Decision to Author是什么意思？是送审的意思吗？还以为是拒稿，等了9天了，还是这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jul 22 08:27:36 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194952, encodeId=1c4e219495215, content=Waiting to Send Decision to Author拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1c29228475, createdName=ms5000002109861368, createdTime=Sun Mar 24 00:19:34 CST 2024, time=2024-03-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=890079, encodeId=7e898900e9c0, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化研究 经验分享：今年首个IF6.0，刚中了一篇，整体要求还是很高，审稿人很专业，要求上传所有原始数据，测序数据要求上传NCBI等公共数据库。很有潜力的乳腺专刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be12166263, createdName=164205595_15230006, createdTime=Sun Oct 04 14:11:33 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183307, encodeId=893b218330e6d, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：未果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:07:04 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2183306, encodeId=0e6d218330648, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:06:27 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2131030, encodeId=8cae2131030ea, content=给共同作者发送了确认邮件是送审之前还是之后呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec888314364, createdName=ms5000000878333462, createdTime=Mon May 08 22:22:18 CST 2023, time=2023-05-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2124134, encodeId=87dc2124134d3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：“Manuscript Under Consideration” 都两个月了，应该是送审了吧，审稿速度真的好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82456516525, createdName=ms5000002097440921, createdTime=Thu Apr 06 16:03:46 CST 2023, time=2023-04-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1226584, encodeId=00891226584a5, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:08:09 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226583, encodeId=b29a12265835b, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:07:34 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193778, encodeId=b3881193e783d, content=<a href='/topic/show?id=b40310445682' target=_blank style='color:#2F92EE;'>#期刊推荐#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104456, encryptionId=b40310445682, topicName=期刊推荐)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=梅斯助教, createdTime=Tue Feb 15 21:44:47 CST 2022, time=2022-02-15, status=1, ipAttribution=)]

2020-10-04 164205595_15230006

审稿速度:3.0 | 投稿命中率:25.0
偏重的研究方向：转化研究
经验分享：今年首个IF6.0，刚中了一篇，整体要求还是很高，审稿人很专业，要求上传所有原始数据，测序数据要求上传NCBI等公共数据库。很有潜力的乳腺专刊！

346 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1001581, encodeId=bf861001581eb, content=有没有大神知道Waiting to Send Decision to Author是什么意思？是送审的意思吗？还以为是拒稿，等了9天了，还是这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jul 22 08:27:36 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194952, encodeId=1c4e219495215, content=Waiting to Send Decision to Author拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1c29228475, createdName=ms5000002109861368, createdTime=Sun Mar 24 00:19:34 CST 2024, time=2024-03-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=890079, encodeId=7e898900e9c0, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化研究 经验分享：今年首个IF6.0，刚中了一篇，整体要求还是很高，审稿人很专业，要求上传所有原始数据，测序数据要求上传NCBI等公共数据库。很有潜力的乳腺专刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be12166263, createdName=164205595_15230006, createdTime=Sun Oct 04 14:11:33 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183307, encodeId=893b218330e6d, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：未果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:07:04 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2183306, encodeId=0e6d218330648, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:06:27 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2131030, encodeId=8cae2131030ea, content=给共同作者发送了确认邮件是送审之前还是之后呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec888314364, createdName=ms5000000878333462, createdTime=Mon May 08 22:22:18 CST 2023, time=2023-05-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2124134, encodeId=87dc2124134d3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：“Manuscript Under Consideration” 都两个月了，应该是送审了吧，审稿速度真的好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82456516525, createdName=ms5000002097440921, createdTime=Thu Apr 06 16:03:46 CST 2023, time=2023-04-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1226584, encodeId=00891226584a5, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:08:09 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226583, encodeId=b29a12265835b, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:07:34 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193778, encodeId=b3881193e783d, content=<a href='/topic/show?id=b40310445682' target=_blank style='color:#2F92EE;'>#期刊推荐#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104456, encryptionId=b40310445682, topicName=期刊推荐)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=梅斯助教, createdTime=Tue Feb 15 21:44:47 CST 2022, time=2022-02-15, status=1, ipAttribution=)]

2024-01-22 ms5000000900542983 来自江苏省

审稿速度:6.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤
经验分享：未果

17 0

[GetPortalCommentsPageByObjectIdResponse(id=1001581, encodeId=bf861001581eb, content=有没有大神知道Waiting to Send Decision to Author是什么意思？是送审的意思吗？还以为是拒稿，等了9天了，还是这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jul 22 08:27:36 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194952, encodeId=1c4e219495215, content=Waiting to Send Decision to Author拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1c29228475, createdName=ms5000002109861368, createdTime=Sun Mar 24 00:19:34 CST 2024, time=2024-03-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=890079, encodeId=7e898900e9c0, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化研究 经验分享：今年首个IF6.0，刚中了一篇，整体要求还是很高，审稿人很专业，要求上传所有原始数据，测序数据要求上传NCBI等公共数据库。很有潜力的乳腺专刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be12166263, createdName=164205595_15230006, createdTime=Sun Oct 04 14:11:33 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183307, encodeId=893b218330e6d, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：未果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:07:04 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2183306, encodeId=0e6d218330648, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:06:27 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2131030, encodeId=8cae2131030ea, content=给共同作者发送了确认邮件是送审之前还是之后呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec888314364, createdName=ms5000000878333462, createdTime=Mon May 08 22:22:18 CST 2023, time=2023-05-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2124134, encodeId=87dc2124134d3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：“Manuscript Under Consideration” 都两个月了，应该是送审了吧，审稿速度真的好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82456516525, createdName=ms5000002097440921, createdTime=Thu Apr 06 16:03:46 CST 2023, time=2023-04-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1226584, encodeId=00891226584a5, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:08:09 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226583, encodeId=b29a12265835b, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:07:34 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193778, encodeId=b3881193e783d, content=<a href='/topic/show?id=b40310445682' target=_blank style='color:#2F92EE;'>#期刊推荐#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104456, encryptionId=b40310445682, topicName=期刊推荐)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=梅斯助教, createdTime=Tue Feb 15 21:44:47 CST 2022, time=2022-02-15, status=1, ipAttribution=)]

2024-01-22 ms5000000900542983 来自江苏省

审稿速度:6.0 | 投稿命中率:25.0
经验分享：未投

16 0

[GetPortalCommentsPageByObjectIdResponse(id=1001581, encodeId=bf861001581eb, content=有没有大神知道Waiting to Send Decision to Author是什么意思？是送审的意思吗？还以为是拒稿，等了9天了，还是这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jul 22 08:27:36 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194952, encodeId=1c4e219495215, content=Waiting to Send Decision to Author拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1c29228475, createdName=ms5000002109861368, createdTime=Sun Mar 24 00:19:34 CST 2024, time=2024-03-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=890079, encodeId=7e898900e9c0, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化研究 经验分享：今年首个IF6.0，刚中了一篇，整体要求还是很高，审稿人很专业，要求上传所有原始数据，测序数据要求上传NCBI等公共数据库。很有潜力的乳腺专刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be12166263, createdName=164205595_15230006, createdTime=Sun Oct 04 14:11:33 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183307, encodeId=893b218330e6d, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：未果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:07:04 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2183306, encodeId=0e6d218330648, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:06:27 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2131030, encodeId=8cae2131030ea, content=给共同作者发送了确认邮件是送审之前还是之后呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec888314364, createdName=ms5000000878333462, createdTime=Mon May 08 22:22:18 CST 2023, time=2023-05-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2124134, encodeId=87dc2124134d3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：“Manuscript Under Consideration” 都两个月了，应该是送审了吧，审稿速度真的好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82456516525, createdName=ms5000002097440921, createdTime=Thu Apr 06 16:03:46 CST 2023, time=2023-04-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1226584, encodeId=00891226584a5, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:08:09 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226583, encodeId=b29a12265835b, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:07:34 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193778, encodeId=b3881193e783d, content=<a href='/topic/show?id=b40310445682' target=_blank style='color:#2F92EE;'>#期刊推荐#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104456, encryptionId=b40310445682, topicName=期刊推荐)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=梅斯助教, createdTime=Tue Feb 15 21:44:47 CST 2022, time=2022-02-15, status=1, ipAttribution=)]

2023-05-08 ms5000000878333462 来自湖南省

给共同作者发送了确认邮件是送审之前还是之后呀

46 0

[GetPortalCommentsPageByObjectIdResponse(id=1001581, encodeId=bf861001581eb, content=有没有大神知道Waiting to Send Decision to Author是什么意思？是送审的意思吗？还以为是拒稿，等了9天了，还是这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jul 22 08:27:36 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194952, encodeId=1c4e219495215, content=Waiting to Send Decision to Author拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1c29228475, createdName=ms5000002109861368, createdTime=Sun Mar 24 00:19:34 CST 2024, time=2024-03-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=890079, encodeId=7e898900e9c0, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化研究 经验分享：今年首个IF6.0，刚中了一篇，整体要求还是很高，审稿人很专业，要求上传所有原始数据，测序数据要求上传NCBI等公共数据库。很有潜力的乳腺专刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be12166263, createdName=164205595_15230006, createdTime=Sun Oct 04 14:11:33 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183307, encodeId=893b218330e6d, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：未果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:07:04 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2183306, encodeId=0e6d218330648, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:06:27 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2131030, encodeId=8cae2131030ea, content=给共同作者发送了确认邮件是送审之前还是之后呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec888314364, createdName=ms5000000878333462, createdTime=Mon May 08 22:22:18 CST 2023, time=2023-05-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2124134, encodeId=87dc2124134d3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：“Manuscript Under Consideration” 都两个月了，应该是送审了吧，审稿速度真的好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82456516525, createdName=ms5000002097440921, createdTime=Thu Apr 06 16:03:46 CST 2023, time=2023-04-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1226584, encodeId=00891226584a5, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:08:09 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226583, encodeId=b29a12265835b, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:07:34 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193778, encodeId=b3881193e783d, content=<a href='/topic/show?id=b40310445682' target=_blank style='color:#2F92EE;'>#期刊推荐#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104456, encryptionId=b40310445682, topicName=期刊推荐)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=梅斯助教, createdTime=Tue Feb 15 21:44:47 CST 2022, time=2022-02-15, status=1, ipAttribution=)]

2023-04-06 ms5000002097440921 来自上海

审稿速度:3.0 | 投稿命中率:50.0
经验分享：“Manuscript Under Consideration” 都两个月了，应该是送审了吧，审稿速度真的好慢呀

41 0

[GetPortalCommentsPageByObjectIdResponse(id=1001581, encodeId=bf861001581eb, content=有没有大神知道Waiting to Send Decision to Author是什么意思？是送审的意思吗？还以为是拒稿，等了9天了，还是这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jul 22 08:27:36 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194952, encodeId=1c4e219495215, content=Waiting to Send Decision to Author拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1c29228475, createdName=ms5000002109861368, createdTime=Sun Mar 24 00:19:34 CST 2024, time=2024-03-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=890079, encodeId=7e898900e9c0, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化研究 经验分享：今年首个IF6.0，刚中了一篇，整体要求还是很高，审稿人很专业，要求上传所有原始数据，测序数据要求上传NCBI等公共数据库。很有潜力的乳腺专刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be12166263, createdName=164205595_15230006, createdTime=Sun Oct 04 14:11:33 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183307, encodeId=893b218330e6d, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：未果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:07:04 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2183306, encodeId=0e6d218330648, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:06:27 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2131030, encodeId=8cae2131030ea, content=给共同作者发送了确认邮件是送审之前还是之后呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec888314364, createdName=ms5000000878333462, createdTime=Mon May 08 22:22:18 CST 2023, time=2023-05-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2124134, encodeId=87dc2124134d3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：“Manuscript Under Consideration” 都两个月了，应该是送审了吧，审稿速度真的好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82456516525, createdName=ms5000002097440921, createdTime=Thu Apr 06 16:03:46 CST 2023, time=2023-04-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1226584, encodeId=00891226584a5, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:08:09 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226583, encodeId=b29a12265835b, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:07:34 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193778, encodeId=b3881193e783d, content=<a href='/topic/show?id=b40310445682' target=_blank style='color:#2F92EE;'>#期刊推荐#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104456, encryptionId=b40310445682, topicName=期刊推荐)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=梅斯助教, createdTime=Tue Feb 15 21:44:47 CST 2022, time=2022-02-15, status=1, ipAttribution=)]

2022-06-15 1253f167m53暂无昵称

无

45 0

[GetPortalCommentsPageByObjectIdResponse(id=1001581, encodeId=bf861001581eb, content=有没有大神知道Waiting to Send Decision to Author是什么意思？是送审的意思吗？还以为是拒稿，等了9天了，还是这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jul 22 08:27:36 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194952, encodeId=1c4e219495215, content=Waiting to Send Decision to Author拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1c29228475, createdName=ms5000002109861368, createdTime=Sun Mar 24 00:19:34 CST 2024, time=2024-03-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=890079, encodeId=7e898900e9c0, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化研究 经验分享：今年首个IF6.0，刚中了一篇，整体要求还是很高，审稿人很专业，要求上传所有原始数据，测序数据要求上传NCBI等公共数据库。很有潜力的乳腺专刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be12166263, createdName=164205595_15230006, createdTime=Sun Oct 04 14:11:33 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183307, encodeId=893b218330e6d, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：未果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:07:04 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2183306, encodeId=0e6d218330648, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:06:27 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2131030, encodeId=8cae2131030ea, content=给共同作者发送了确认邮件是送审之前还是之后呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec888314364, createdName=ms5000000878333462, createdTime=Mon May 08 22:22:18 CST 2023, time=2023-05-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2124134, encodeId=87dc2124134d3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：“Manuscript Under Consideration” 都两个月了，应该是送审了吧，审稿速度真的好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82456516525, createdName=ms5000002097440921, createdTime=Thu Apr 06 16:03:46 CST 2023, time=2023-04-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1226584, encodeId=00891226584a5, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:08:09 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226583, encodeId=b29a12265835b, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:07:34 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193778, encodeId=b3881193e783d, content=<a href='/topic/show?id=b40310445682' target=_blank style='color:#2F92EE;'>#期刊推荐#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104456, encryptionId=b40310445682, topicName=期刊推荐)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=梅斯助教, createdTime=Tue Feb 15 21:44:47 CST 2022, time=2022-02-15, status=1, ipAttribution=)]

2022-06-15 1253f167m53暂无昵称

无

45 0

[GetPortalCommentsPageByObjectIdResponse(id=1001581, encodeId=bf861001581eb, content=有没有大神知道Waiting to Send Decision to Author是什么意思？是送审的意思吗？还以为是拒稿，等了9天了，还是这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18525506506, createdName=ms4000001058776765, createdTime=Thu Jul 22 08:27:36 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194952, encodeId=1c4e219495215, content=Waiting to Send Decision to Author拒稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1c29228475, createdName=ms5000002109861368, createdTime=Sun Mar 24 00:19:34 CST 2024, time=2024-03-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=890079, encodeId=7e898900e9c0, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：转化研究 经验分享：今年首个IF6.0，刚中了一篇，整体要求还是很高，审稿人很专业，要求上传所有原始数据，测序数据要求上传NCBI等公共数据库。很有潜力的乳腺专刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be12166263, createdName=164205595_15230006, createdTime=Sun Oct 04 14:11:33 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183307, encodeId=893b218330e6d, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：未果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:07:04 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2183306, encodeId=0e6d218330648, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59d18404707, createdName=ms5000000900542983, createdTime=Mon Jan 22 22:06:27 CST 2024, time=2024-01-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2131030, encodeId=8cae2131030ea, content=给共同作者发送了确认邮件是送审之前还是之后呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec888314364, createdName=ms5000000878333462, createdTime=Mon May 08 22:22:18 CST 2023, time=2023-05-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2124134, encodeId=87dc2124134d3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：“Manuscript Under Consideration” 都两个月了，应该是送审了吧，审稿速度真的好慢呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82456516525, createdName=ms5000002097440921, createdTime=Thu Apr 06 16:03:46 CST 2023, time=2023-04-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1226584, encodeId=00891226584a5, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:08:09 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226583, encodeId=b29a12265835b, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6632550457, createdName=1253f167m53暂无昵称, createdTime=Wed Jun 15 13:07:34 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193778, encodeId=b3881193e783d, content=<a href='/topic/show?id=b40310445682' target=_blank style='color:#2F92EE;'>#期刊推荐#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104456, encryptionId=b40310445682, topicName=期刊推荐)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=梅斯助教, createdTime=Tue Feb 15 21:44:47 CST 2022, time=2022-02-15, status=1, ipAttribution=)]

2022-02-15 梅斯助教

#期刊推荐#

87 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务